Aims: This open-label prospective phase I/IIa clinical study used autologous bone marrow-derived mesenchymal stromal cells (BM-MSCs) followed by mesenchymal stromal cells conditioned media (MSC-CM) for the first time to treat multiple sclerosis (MS) patients. The primary goal was to assess the safety and feasibility and the secondary was efficacy. The correlation between the MSC-CM content and treatment outcome was investigated.
| INTRODUCTION
Multiple sclerosis (MS) was described more than 150 years ago by the French neurologist Jean-Martin Charcot after finding distinctive postmortem scars in the brain of a lady who had presented to him with tremor, slurred speech, and abnormal eye movement.
1 Current knowledge defines MS as a demyelinating, neurodegenerative, and neuroinflammatory disease of the CNS. 2 The disease leads to a progressive disabling course over the period of one to two decades in the majority of the young adult patients it affects. 3 There were no effective treatments for this disease until the early nineties of the last century when interferons and glatiramer acetate were introduced and accepted as quite safe and moderately effective treatments that improved only the relapse rate in one-third of patients but did not change the progressive course of the disease. During the past two decades, other treatment modalities (biological, monoclonal, and recently oral agents) have been introduced with better outcome compared to interferon. But all the available therapy for MS has some limitations related to intolerability, efficacy, or safety. [4] [5] [6] [7] Stem cell therapy may be an ideal intervention;
MSCs are considered to have multiple capabilities, including homing to the site of injury, halting the destructive inflammation, and regenerating the damaged areas of the CNS. [8] [9] [10] MSCs have also been found to differentiate into the damaged cell types, neurons and glial cells, given the appropriate environment. 11, 12 In addition, The MSC secretome found in the growth and expansion media, also called, conditioned media (MSC-CM), has been investigated for its therapeutic potential. 13, 14 For instance, MSCs secrete certain proregenerative mediators that tip the equation toward repair rather than destruction, including cytokines, chemokines, and growth factors. 15, 16 MSCs also produce neuroprotective factors that promote the survival and regeneration of neurons. 17, 18 Furthermore, they have been found to produce many immune-modulatory proteins that affect the adaptive as well as the innate cells. 13 In vitro, MSC-CM from MS patients attenuated the secretion of inflammatory cytokines in a microglia and oligodendrocyte model cell lines. 19 The intravenous injection of MSC-CM without MSCs in an animal model of MS-the experimental autoimmune encephalomyelitis (EAE)-showed significant improvement indicating the importance of MSC-CM in the repair process. 20 In another in vivo study, MSC-CM attenuated neural degeneration in a spinocerebellar ataxia mice model. 21 
| METHODS

| Patients
Patients enrolled had a clinically definite MS based on McDonald's criteria. 29, 30 The inclusion criteria indicated a failure of at least one-first- 
| Transplantation of BM-MSCs and MSC-CM
BM-MSCs were injected intrathecally into patients by the neurologist immediately after harvest. In addition, at least 50 mL of mycoplasmatested MSC-CM was preserved at −80°C for subsequent injection and analysis. After a month interval, an average volume of 18 mL of thawed MSC-CM corresponding to each patient's MSCs was given in a similar intrathecal manner as the MSCs.
After each injection, patients were observed in the outpatient clinic for at least one hour. They were followed up closely for the first week for any health-related incident. They presented to the clinic at 3,6,12 months after treatment for full examinations as described below. 
| Patients
| Visual analysis
The eye condition was not a recruitment criteria and it was used for safety assessment as well as efficacy in an examiner blinded method.
This included best corrected visual acuity, pupillary examination, ocu- Interferon MXT 4 40
Interferon Nat 1 10
Interferon &SC 1 10 MXT, Mitoxantrone; Nat, Natalizumab; SC, stem cell; MSCs, mesenchymal stem cells; CM, conditioned media.
Mean (±SD) Range
(OCT), and automated visual fields. For each patient, the worst presenting eye at baseline was followed up and included in the analysis (Table 3 ). In the electrophysiology test, the VEP latency-100 was used which measures the speed of signal transmission in milliseconds (ms), with a normal range of 100 ± 7 ms. For the OCT, retinal nerve fiber layer thickness (μm) was measured with 100 um being normal.
| Radiological evaluation
Magnetic resonance imaging (MRI) was performed on a 3-Tesla Verio system (Siemens Medical Systems, Erlangen, Germany). All patients underwent an MRI scanning at baseline (less than 72 hours prior to stem cell injection) then at 3, 6, and 12 months post-MSCs injection.
The detailed imaging sequences protocol of the brain and those of the cervical and thoracic spine can be found in Appendix S2. T2-weighted FLAIR and T1-weighted MPRAGE images were generated for all patients.
The T2-hyperintense lesion volume measurements were obtained using a semi-automated segmentation technique based on Fuzzy connections algorithm in JIM software (Jim version 3; Xinapse Systems, Colchester, England). 
| Measuring inflammatory biomarkers CM content
Cryopreserved BM-MSCs from 7 enrolled patients were thawed, cultured until they reached 80% confluence after which MSC-CM was removed to analyze its content. The Luminex multiplex ELISA technology was used, samples were tested in triplicates, and culture media were used as a reference. The concentration in pg/mL of 27 inflammatory biomarkers was assayed according to the manufacturer's directions (Bio-Rad, Pro-Human Cytokine 27-Plex Immunoassay). 
| Statistics
Wilcoxon matched-pairs signed rank test was used to assess differences between baseline and 12 months posttreatment presented in Table 3 . Results were also analyzed for 3 and 6 months (Table S2) . For analytes concentrations, Mann-Whitney test was used in the DataPro analysis software.
| RESULTS
| Safety assessments
No patient had any treatment-related life-threatening adverse event (AE) from the time of injection through the follow-up year. Table 2 lists the recorded AEs for the 15 treated patients. The transient minor
AEs experienced by at least one patient following the administration of MSCs are summarized in Table 2 . No cases of meningitis, encephalopathy, seizures, or allergic reactions were experienced by any patient. All patients' records were filed in a paper format. 
| Efficacy assessments
| Clinical assessment
The EDSS was the primary efficacy parameter in this study; it is the most widely used test by neurologists for MS patients. The average overall change in the EDSS was -0. 1 (±2.16) points with a change range of (−4 to 3) points (Table 2) . Of the 10 patients, 4 corresponding to 40% showed no change in their EDSS, another 40% of patients deteriorated while 20% improved (MS1, MS9) ( Figure 2 and Table S1 ). 
| MRI assessments
The number of T2 brain white matter lesions remained unchanged between baseline and 12-month scans in 60% of patients, and it increased in 40% with an overall rise of 4.3 ±7.0 lesions (Table 3) .
On the other hand, 90% of patients did not show any change in the number of spinal cord white matter (SC-WM) lesions, while the number increased in 10%. However, the number of enhancing T1-lesions in both the brain and spinal cord has decreased in 20%, increased in 30%, and has not changed in 50% of patients.
Volumetric studies of the white matter lesions showed that the T2-lesion volume did not change in 20% of patients, and it increased in 70% and decreased in 10% of patients (Figure 2 ). There was a 
| Visual assessments
Although many patients reported subjective improvement in the quality of vision, there were no positive statistically significant changes in all of the studied parameters including vision, color vision, and the objective measures such as VEP and OCT (Figure 3 ). On the contrary, Table 3 shows a trend of a decreased mean retinal nerve fiber layer (RNFL) on OCT with a decrease of −0.8 (±4.15) μm. In addition, the VEP results showed a trend of increased latency of the electrical conduction of the optic nerves with 0.22 (±7.25) milliseconds (ms) which was noticeable even at 3 and 6 months posttreatment (Table   S2 ). Despite minimal changes in VEP and OCT, the vision remained stable in all patients throughout the study.
| MSC-CM inflammatory profile
The human inflammatory panel was used to examine any difference 
| DISCUSSION
MS is still difficult to treat, and many patients will become disabled at some point, and thus, the need for a treatment that is both safe and effective is beyond any doubt.
MSCs continue to be investigated as a treatment option for several neurological diseases. The rationale behind adding the MSC-CM in this study was to boost the dual; regenerative, and immune-modulatory In previous clinical studies, the optimal route of stem cell injection, frequency, and number of cells injected has varied and is yet to be determined. [22] [23] [24] [25] [26] [27] [28] In a preclinical study, direct intraventricular MSCs injection has been reported to be more effective in the EAE model compared to the intravenous route. 38 The intrathecal route has been previously used for MS patients but with lower numbers of injected MSCs. 23, 24 In this trial, we report injecting safely the highest reported dose of autologous MSCs into MS patients (93-168*10 6 ) via the intrathecal route. It was followed a month later with the MS-CM (15-20 mL).
In the present study-to the best of our knowledge-a cellular treat- 26 In this study, MSCs were given immediately after expansion to limit cell death due to cryopreservation. The MSCs were also cultured using a matching blood group human platelet lysate media supplement instead of the usually used fetal calf serum.
These are technical aspects of the MSCs culture that might have contributed to the safety outcome and reduced sensitization or inflammatory reactions.
Due to the small number and heterogeneity of enrolled patients in terms of the type of MS, duration of the disease, and baseline EDSS score, it was not possible to reach statistical significance and draw definite conclusions. The withdrawal of 3 of the 15 enrolled patients may indicate some hurdles to the intrathecal route in some patients which needs to be considered in planning future trials. For the remaining 10 patients, a trend of decreased EDSS in patients who had failed initial first-or second-line therapy with a percentage of 60% stabilization or improvement is encouraging. Two patients had a remarkable decrease in their EDSS. Both were SPMS, the first patient presented with an EDSS of 5.5 which became 2 at twelve months, while the other patient went from a score of 6 to 1.5 (Table S1 ). This had a great impact on all aspects of their lives which was also detected by improved 9-HPT and the T25FW of more than 20% in each test for each patient (Table S1 ).
The original Multiple Sclerosis Functional Composite (MSFC) test
consists of three components, and the composite score is created by converting the score of each of the three components into a z-score.
However, the original MSFC test does not have a clear meaning in MS progression. 39 In the present study, we used two components of its components, the 9-HPT and the T25FW. With these two tests, a 20% change had been shown to be sensitive in assessing disease progression.
40
The cognitive aspect of MS has been well documented as part of the MS manifestations. 41 It is nevertheless disregarded in the efficacy assessments of many therapeutic options. The (MMSE) psychocognitive test indicated patients were normal at baseline, and 30% of patients showed a decrease in the score which could reflect a progression in the disease, although a report of the MMSE's low sensitivity in assessing cognitive decline in patients would make it less conclusive.
42
One of the two patients who had improved on the EDSS scale had a decrease of 18 enhanced lesions while the total number and volume of brain lesions increased. While the other patient had one more enhanced lesion at 12 months with an increase in total number and volume of brain lesions (Table S1) Moreover, the ophthalmological results did not correlate with the EDSS score, while some patients improved in these outcome measures, their overall assessment was either stable or worse. Our results were similar to a previous report that used autologous MSCs and could not identify any significant effects on color vision, visual fields, macular volume, and retinal nerve fiber layer thickness. 25 However, that study documented minimal improvement in visual acuity and visual evoked response latency, with an increase in optic nerve area.
On the other hand, results of another study showed vision and visual contrast testing improvement in 2 of 4 patients with unchanged RNFL thickness in 3 patients and a decrease in one.
23
The lack of a control group is a drawback in this cellular therapy on MS which is due to the clinical and pathological heterogeneity of the MS patients that makes it difficult to identify a matching group. In one study, this was bypassed by a latency period of 6 months between groups so that every patient is his own control, a strategy worth considering in future MS trials but may be with a longer latency period.
26
Nevertheless, it can be clearly observed that most patients improved in one of the efficacy endpoints reflecting diversity of responses (Table S1 ). This could reflect (i) the heterogeneity of patients included in terms of type, areas affected, and severity of MS, (ii) the different homing and therapeutic potential of the MSCs injected, and (iii) the different composition of MSC-CM and its potential to reverse differently the disease aspects examined in this study. 
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